Durham, NC-- BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced today the launch of Clinical Innovations, a new continuing education program for clinical laboratory professionals that consists of courses on timely women's health diagnostics and laboratory management issues developed and taught by leading clinicians and laboratory experts.
"Clinical laboratory professionals are increasingly challenged to keep up with trends and issues in the laboratory, as well as new technologies and processes, while balancing growing workloads," said Wayne Brinster, Vice President and General Manager, Women's Health and Cancer, BD Diagnostics. "Clinical Innovations is designed to provide them with a high-quality and cost-efficient way to stay current on new developments and meet their continuing education requirements."
Clinical Innovations will consist of modules which will be updated quarterly and presented via DVD. After reviewing the DVD, laboratory personnel can visit a web portal to take a test. Upon successful completion of the test, participants will receive an accredited continuing education unit (CEU) certificate from the American Society for Clinical Laboratory Science's P.A.C.E. ® (Professional Acknowledgement for Continuing Education) Program.
Initially scheduled program courses are:
The program tools will be disseminated by BD associates directly to clinical laboratories. BD Diagnostics focuses on women's health and cancer by delivering high-quality, productivity-enhancing molecular diagnostics solutions for major women's health conditions to clinical laboratories worldwide. Its diagnostic instrument systems and assays are used by leading laboratories for the detection and screening of chlamydia, gonorrhea, and vaginitis, as well as cervical cancer. The business is also actively developing tests for herpes simplex virus (HSV-1 and HSV-2) and human papillomavirus (HPV), as well as for ovarian and breast cancer biomarkers.
About BD
BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.
This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; and changes in healthcare or other governmental regulation; issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.
